<DOC>
	<DOCNO>NCT00440895</DOCNO>
	<brief_summary>- Abciximab administration safe reduces ischemic complication patient undergo rescue PCI fail thrombolysis compare placebo . - Abciximab improves angiographic score ventricular function rescue-PCI compare placebo . - Intracoronary abciximab administration effective intravenous route administration term acute mid-term angiographic clinical result . - Intracoronary intravenous bolus administration abciximab dose provide similar platelet aggregation inhibition ( PAI ) . - There significant relationship PAI abciximab administration index myocardial perfusion . - Routine use Sirolimus-eluting stent ( Cypher , Cordis , US ) rescue-PCI associate low rate target vessel revascularization . - Cardiac MRI early late rescue-PCI provide detailed information myocardial injury irreversible necrosis , correlate angiographic perfusion score . - After uncomplicated trans-radial rescue PCI , patient retransferred early referring center .</brief_summary>
	<brief_title>A Randomized Trial Early Discharge After Trans-radial Stenting Coronary Arteries Acute MI Rescue-PCI</brief_title>
	<detailed_description>OBJECTIVES AND END-POINTS The objective present pilot study ass 1 ) benefit safety abciximab i.c . i.v . compare placebo rescue PCI trans-radial approach , 2 ) relationship platelet aggregation inhibition perfusion score demonstrate 3 ) good perfusion score i.c . abciximab compare i.v . abciximab placebo . The Primary ANGIOGRAPHIC end-point TIMI score myocardial blush grade rescue-PCI baseline 6-months follow-up . The Secondary CLINICAL end-point : - composite death , stroke , repeat-myocardial infarction , urgent target vessel revascularization major bleeding 30 day rescue PCI . - composite death , repeat-myocardial infarction , repeat target vessel revascularization 6 month follow rescue PCI . The Secondary PLATELETS end-point proportion patient platelet aggregation inhibition ≥ 95 % mean platelet aggregation inhibition 10 minute post-bolus administration . The Secondary ANGIOGRAPHIC end-points angiographic late loss restenosis rate ( Diameter stenosis ≥ 50 % ) culprit artery . Other exploratory end-points include feasibility safety early transfer refer hospital uncomplicated primary PCI , cardiac MRI measurement PAI 6 hr bolus administration .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Patient acute myocardial infarction eligible rescue PCI within 24 hr symptom . Failed thrombolysis ( define less 50 % reduction STelevation 90 min ECG lead previous maximal STsegment elevation ) . Patient &gt; 18 year old . Patient treat interventional cardiologist agree randomization . Patient inform randomization process sign inform consent . Diagnostic therapeutic intervention perform transradial/transulnar approach . The culprit lesion native coronary artery identify suitable immediate angioplasty stent implantation . Age &gt; 75 year old Body weight &lt; 65 kg Concurrent participation investigational study Intolerance allergy ASA , clopidogrel ticlopidine preclude treatment 12 month Any significant blood dyscrasia , diathesis INR &gt; 2.0 . Any clinical contraindication abciximab administration i.e . know structural intracranial lesion , thrombocytopenia ( &lt; 100,000 ) , hemoglobin level &lt; 10 g/dl Patient receive one dose thrombolytic within 24 hour symptoms Previous treatment glycoprotein IIbIIIa inhibitor within 30 day Perceived increased risk intracranial severe bleed i.e . previous stroke/TIA , alteration consciousness , recent trauma major surgery . Uncontrolled high blood pressure i.e . systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 100 mmHg . Life expectancy le 6 month owe noncardiac cause Evident cardiogenic shock</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Coronary artery stenting</keyword>
	<keyword>Trans-radial</keyword>
	<keyword>Intracoronary</keyword>
	<keyword>Rescue-PCI</keyword>
</DOC>